Review ArticleClinical Review

Chemoprevention of Prostate Cancer: Myths and Realities

Philippe D. Violette and Fred Saad
The Journal of the American Board of Family Medicine January 2012, 25 (1) 111-119; DOI: https://doi.org/10.3122/jabfm.2012.01.110117

References

  1. 1.↵
    American Cancer Society. Cancer facts and figures, 2010. Atlanta, GA: American Cancer Society; 2010.
  2. 2.↵
    American Cancer Society. Breast cancer facts and figures, 2010. Atlanta, GA: American Cancer Society; 2010.
  3. 3.↵
    1. Altekruse SF,
    2. Kosary CL,
    3. Kracho M,
    4. et al
    . SEER cancer statistics review, 1975–2007. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2007/. Accessed November 14, 2011.
  4. 4.↵
    1. Bill-Axelson A,
    2. Holmberg L,
    3. Ruutu M,
    4. et al
    . Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977–84.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Bolla M,
    2. Gonzalez D,
    3. Warde P,
    4. et al
    . Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295–300.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Bolla M,
    2. Collette L,
    3. Blank L,
    4. et al
    . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–6.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Crawford ED,
    2. Eisenberger MA,
    3. McLeod DG,
    4. et al
    . A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–24.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Tannock IF,
    2. deWit R,
    3. Berry WR,
    4. et al
    . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–12.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Tran C,
    2. Ouk S,
    3. Clegg NJ,
    4. et al
    . Development of a second generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787–90.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Smith MR,
    2. Egerdie B,
    3. Toriz NH,
    4. et al
    . Denosumab in men receiving androgen-deprevation therapy for prostate cancer. N Engl J Med 2009; 361: 745–75.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Sonpavde G,
    2. Periman PO,
    3. Bernold D,
    4. et al
    . Sunitinib malate for metestatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21: 319–24.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Sanda MG,
    2. Dunn RL,
    3. Michalski J,
    4. et al
    . Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med 2008; 358: 1250–61.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Wilson LS,
    2. Tesoro R,
    3. Elkin EP,
    4. et al
    . Cumulative cost pattern comparison of prostate cancer treatments. Cancer 2007; 109: 518–27.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Thompson IM,
    2. Goodman PJ,
    3. Tangen CM,
    4. et al
    . The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–24.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Andriole GL,
    2. Bostwick DG,
    3. Brawley OW,
    4. et al
    . Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192–202.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Lippman SM,
    2. Klein EA,
    3. Goodman PJ,
    4. et al
    . Effect of selenium and vitamin E on risk of prostate cancer and other cancers. JAMA 2009; 301: 39–51.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Thompson IM,
    2. Kouril M,
    3. Klein EA,
    4. Coltman CA,
    5. Ryan A,
    6. Goodman PJ
    . The prostate cancer prevention trial: current status and lessons learned. Urology 2001; 57 (Suppl 4A): 230–4.
    OpenUrlPubMedWeb of Science
  18. 18.↵
    1. Thompson IM,
    2. Chi C,
    3. Ankerst DP,
    4. et al
    . Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 1128–33.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Thompson IM,
    2. Tangen CM,
    3. Goodman PJ,
    4. et al
    . Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007; 177: 1749–52.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. McConnell JD,
    2. Reohrborn CG,
    3. Bautista OM,
    4. et al
    . The long term effect of doxazosin, finastaride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–98.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Lucia MS,
    2. Darke AK,
    3. Goodman PJ,
    4. et al
    . Pathologic characteristics of cancers detected in the prostate cancer prevention trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res 2008; 1 (3): 167–73.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Kramer BS,
    2. Hagerty LK,
    3. Justman S,
    4. et al
    . Use of 5 alpha reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. J Urol 2009; 181: 1642–57.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. McConnell JD,
    2. Roehrborn CG,
    3. Bautista OM,
    4. et al
    . The long term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–9.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Roehrborn CG,
    2. Siami P,
    3. Barkin J,
    4. et al
    . The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616–21.
    OpenUrlPubMedWeb of Science
  25. 25.↵
    1. Barkin J,
    2. Reohrborn CG,
    3. Siami P,
    4. et al
    . Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009; 103: 919–26.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Kramer BS,
    2. Hagerty KL,
    3. Justman S,
    4. et al
    . Use of 5 alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/ American Urological Association 2008 clinical practice guideline. J Clin Oncol 2009; 27: 1502–1516.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Theoret MR,
    2. Ning YM,
    3. Zhang JJ,
    4. Justice R,
    5. Keegan P,
    6. Pazdur R
    . The risks and benefits of 5α reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011; 365: 97–9.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Irani J,
    2. Ravery V,
    3. Pariente JL,
    4. et al
    . Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 2002; 168: 1985–8.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Basler JW,
    2. Piazza GA
    . Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 2004; 171: S59–63.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Thompson IM
    . Chemoprevention of prostate cancer: agents and study designs. J Urol 2007; 178: S9–13.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Price D,
    2. Stin B,
    3. Seiber P,
    4. Tutrone R,
    5. Bailen J,
    6. Goluboff E
    . Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double blind, placebo controlled, phase IIB clinical trial. J Urol 2006; 176: 965–71.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Smith MR,
    2. Malkowicz BS,
    3. Chu F,
    4. et al
    . Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multineter phase III study. J Clin Oncol 2008; 26: 1824–9.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Smith MR,
    2. Malkowicz BS,
    3. Chu F,
    4. et al
    . Toremifene increases bone density in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multineter phase III study. J Urol 2008; 179: 152–5.
    OpenUrlPubMedWeb of Science
  34. 34.↵
    1. Bonovas S,
    2. Filioussi K,
    3. Sitaras NM
    . Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123 (4): 899–904.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Klein EA
    . Selenium and vitamin E cancer prevention trial. Ann N Y Acad Sci 2004; 1031: 234–41.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Clark LC,
    2. Combs GF,
    3. Turnbull BW,
    4. et al
    . Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276: 1957–63.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Duffield-Lillico AJ,
    2. Dalkin BL,
    3. Reid ME,
    4. et al
    . Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003; 91: 608–12.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    ATBC Cancer prevention study group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029–35.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Miller ER III.,
    2. Pastor-Barriuso R,
    3. Dalal D,
    4. Riemersma RA,
    5. Appel LJ,
    6. Guallar E
    . Meta-analysis: high-dosage vitamin E supplementation may cause increased all-cause mortality. Ann Intern Med 2005; 142 (1): 37–46.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Bjelakovic G,
    2. Nikoloova D,
    3. Gluud,
    4. LL,
    5. Simonetti RG,
    6. Gluud C
    . Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297 (8): 842–57.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Sesso HD,
    2. Buring JE,
    3. Christen WG,
    4. et al
    . Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008; 300: 2123–33.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Gaziano MJ,
    2. Glynn RJ,
    3. Christen WG,
    4. et al
    . Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009; 301 (1): 52–62.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Druesne-Pecollo N,
    2. Latino-Martel P,
    3. Norat T,
    4. et al
    . Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer 2009; 127: 172–84.
    OpenUrl
  44. 44.↵
    1. Stevens VL,
    2. McCullough ML,
    3. Diver RW,
    4. et al
    . Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control 2005; 16: 643–50.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Schuurman AG,
    2. van den Brandt PA,
    3. Dorant E,
    4. Goldbohm RA
    . Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study. Br J Cancer 1999; 80: 1107–13.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Chavarro JE,
    2. Stampfer MJ,
    3. Hall MN,
    4. Sesso HD,
    5. Ma J
    . A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality. Am J Clin Nutr 2008; 88: 1297–303.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Klein EA,
    2. Thompson IM
    . Update on chemoprevention of prostate cancer. Curr Opin Urol 2004; 14: 143–9.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Moyad MA,
    2. Sakr WA,
    3. Hirano D,
    4. Miller GJ
    . Complementary medicine for prostate cancer: effects of soy and fat consumption. Rev Urol 2001; 3 (Suppl 2): S20–30.
    OpenUrlPubMed
  49. 49.↵
    1. Giovannucci E,
    2. Rimm EB,
    3. Liu Y,
    4. Stampfer MJ,
    5. Willett WC
    . A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002; 94: 391.
  50. 50.↵
    1. Kirsh VA,
    2. Mayne ST,
    3. Peters U,
    4. et al
    . A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 92.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section